Abstracts tagged "anti-TNF therapy"

Abstract Number: 2558 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the 48-Week Run-in Part of a Withdrawal Study (NCT02505542)
Robert B.M. Landewé¹, Désirée van der Heijde², Maxime Dougados³, Xenofon Baraliakos⁴, Filip van Den Bosch⁵, Bengt Hoepken⁶, Karen Thomas⁶ and Lianne S. Gensler⁷, ¹Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Heerlen, Netherlands, ²Leiden University Medical Centre, Leiden, Netherlands, ³Rheumatology B Department, Paris-Descartes University and Cochin Hospital, Paris, France, ⁴Ruhr-University Bochum, Herne, Germany, ⁵Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium, ⁶UCB Pharma, Monheim, Germany, ⁷University of California, San Francisco, CA
Background/Purpose: C-OPTIMISE is the first trial to evaluate whether certolizumab pegol (CZP) can be reduced/discontinued in patients with radiographic(r)-axSpA/ankylosing spondylitis (AS) and non-radiographic(nr)-axSpA achieving sustained…
Abstract Number: 559 • 2018 ACR/ARHP Annual Meeting
Radiographic Progression Based on Baseline Demographics and Disease Characteristics from Three TNF-Alpha Inhibitor Biosimilar Studies in Patients with Rheumatoid Arthritis
Josef S. Smolen¹, Young Mo Kang², Wan-Hee Yoo³, Paul Emery⁴, Michael E Weinblatt⁵, Edward C. Keystone⁶, Mark C. Genovese⁷, Gihyun Myung⁸, Evelyn Hong⁸, Inyoung Baek⁸ and Jeehoon Ghil⁸, ¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²Kyungpook National University School of Medicine, Daegu, Korea, Republic of (South), ³Chonbuk National University School of Medicine, Jeonju, Korea, Republic of (South), ⁴University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Mount Sinai Hospital, Toronto, ON, Canada, ⁷Stanford University Medical Center, Palo Alto, CA, ⁸Samsung Bioepis Co., Ltd., Incheon, Korea, Republic of (South)
Background/Purpose: SB4, SB2, and SB5 are biosimilars of reference etanercept, infliximab, and adalimumab, respectively. Radiographic data were assessed using the modified Total Sharp Score (mTSS)…
Abstract Number: 2580 • 2018 ACR/ARHP Annual Meeting
Predicting Treatment Persistence and Non-Persistence of Newly Initiated TNF Inhibitor Therapy in Ankylosing Spondylitis Patients: A Gender Comparison
Theresa Hunter¹, Atul A. Deodhar², Rebecca Bolce¹, Krista Schroeder¹ and David Sandoval Calderon¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Oregon Health & Science U, Portland, OR
Background/Purpose: The purpose of this study was to compare treatment patterns in the 2 years following the initiation of TNF inhibitor (TNFi) in AS patients.Methods:…
Abstract Number: 584 • 2018 ACR/ARHP Annual Meeting
Changes in CD4+ T and B Cell Profile As Indicator of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis
Borja Hernández-Breijo^1,2, Israel Gañán-Nieto³, Cristina Sobrino³, Victoria Navarro-Compán¹, Ana Martínez^1,2, Carlota García-Hoz³, Javier Bachiller³, María Gema Bonilla Hernán^1,4, Garbiñe Roy⁵, Mónica Vázquez³, Alejandro Balsa^1,6, Luisa María Villar³, Dora Pascual-Salcedo¹, Eulalia Rodríguez-Martín³ and Chamaida Plasencia^1,4, ¹Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, ²Immunology. La Paz University Hospital, Madrid, Spain, ³Immuno-Rheumatology research group, IRYCIS. Ramón y Cajal University Hospital, Madrid, Spain, ⁴Rheumatology, La Paz University Hospital, Madrid, Spain, ⁵Immunology. Ramón y Cajal University Hospital and IRYCIS, Madrid, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: TNF inhibitors (TNFi) are widely used for the treatment of rheumatoid arthritis (RA). This study aims to analyse the profile of peripheral blood mononuclear…
Abstract Number: 2599 • 2018 ACR/ARHP Annual Meeting
The Agreement between TNFi Treatment Responses and Fatigue Responses Is Weak to Moderate Suggesting Heterogeneity between Experienced Fatigue and Joint Inflammation: A Danish Population-Based Cohort Study
Tanja Schjødt Jørgensen¹, Marie Skougaard¹, Rebekka L Hansen¹, Christine Ballegaard¹, Philip J. Mease², Vibeke Strand³, Lene Dreyer⁴ and Lars Erik Kristensen¹, ¹The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen F, Denmark, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁴Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University., Hellerup, Denmark
Background/Purpose: Despite better control of inflammation, e.g. with biological treatments, some patients with psoriatic arthritic (PsA) continue to cite fatigue as one of the most…
Abstract Number: 597 • 2018 ACR/ARHP Annual Meeting
Characteristics of Patients and Predictors of Composite Disease Activity Scores for Switching to Monotherapy Vs Continuing TNF Inhibitor and Methotrexate Combination Therapy in RA: A Retrospective Analysis of the Brigham and Women’s Rheumatoid Arthritis Sequential Study Registry
Nancy A. Shadick¹, Michael E Weinblatt¹, Christine K Iannaccone², Michelle Frits³, Tigwa Davis⁴, Christopher Young⁴, David H. Collier⁵, Mahdi Gharaibeh⁵ and Bradley S. Stolshek⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Health Analytics, LLC, Columbia, MD, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Biologics in combination with methotrexate (MTX) are being incorporated earlier in rheumatoid arthritis (RA) therapy to prevent long-term damage and maintain patient function. While…
Abstract Number: 2603 • 2018 ACR/ARHP Annual Meeting
Efficacy of Tildrakizumab in Etanercept Partial Responders or Nonresponders
Jeffrey Crowley¹, Kim A Papp², Chih-ho Hong³, Jeff Parno⁴, Alan M Mendelsohn⁴, Qing Li⁵ and Nicole Cichanowitz⁵, ¹Bakersfield Dermatology, Bakersfield, CA, ²Probity Medical Research, Waterloo, ON, Canada, ³University of British Columbia, Department of Dermatology and Skin Science and Probity Medical Research, Surrey, BC, Canada, ⁴Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁵Merck & Co., Inc., Kenilworth, NJ
Background/Purpose: Etanercept (ETN), an anti-TNF medication, was among the first biologics approved for psoriasis. Additional psoriasis medications that have been developed, or are in development,…
Abstract Number: 598 • 2018 ACR/ARHP Annual Meeting
Real-World Experience of Effectiveness and Safety of Certolizumab Pegol for Rheumatoid Arthritis in Japan: Single-Center Retrospective Study
Naohiro Sugitani^1,2, Eiichi Tanaka¹, Eisuke Inoue^1,3, Eri Sugano¹, Kumiko Saka¹, Moeko Ochiai¹, Rei Yamaguchi¹, Yoko Shimizu¹, Naoki Sugimoto¹, Katsunori Ikari¹, Ayako Nakajima^1,2, Atsuo Taniguchi¹ and Hisashi Yamanaka⁴, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, ³Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Certolizumab-pegol (CZP) is a sixth antitumor necrosis factor inhibitor for rheumatoid arthritis (RA) in Japan. Several clinical trials were conducted to evaluate the efficacy…
Abstract Number: 2790 • 2018 ACR/ARHP Annual Meeting
Screening of Patients with Adult-Onset Idiopathic Polyarteritis Nodosa for Deficiency of Adenosine Deaminase 2
Oskar Schnappauf¹, Monique Stoffels², Ivona Aksentijevich², Daniel L. Kastner², Peter C. Grayson³, David Cuthbertson⁴, Simon Carette⁵, Sharon A. Chung⁶, Lindsy J. Forbess⁷, Nader A. Khalidi⁸, Curry L. Koening⁹, Carol Langford¹⁰, Carol A. McAlear¹¹, Paul A. Monach¹², Larry W. Moreland¹³, Christian Pagnoux¹⁴, Philip Seo¹⁵, Jason Springer¹⁶, Antoine G. Sreih¹⁷, Kenneth J. Warrington¹⁸, Steven R. Ytterberg¹⁸ and Peter A. Merkel¹⁹, ¹NHGRI, National Institutes of Health, Bethesda, MD, ²Metabolic, Cardiovascular, and Inflammatory Disease Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD, ⁴Biostatistics and Informatics, Department of Pediatrics, Department of Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁵Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ⁶Russell/Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA, ⁷Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatology, McMaster University, Hamilton, ON, Canada, ⁹Rheumatology, Division of Rheumatology, University of Utah, Salt Lake City, UT, ¹⁰Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹²Section of Rheumatology, Boston University School of Medicine, Boston, MA, ¹³Division of Rheumatology and Clinical Immunology, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁴Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹⁵Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹⁶Department of Internal Medicine, The University of Kansas Medical Center, Division of Allergy, Clinical Immunology & Rheumatology, Kansas City, KS, ¹⁷Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁸Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, ¹⁹Division of Rheumatology and the Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is the first described type of monogenic vasculitis. Patients usually present in childhood, but age of onset, disease…
Abstract Number: 618 • 2018 ACR/ARHP Annual Meeting
Blood Lymphocytes Subtypes As Biomarkers for Early Identification of Optimal Responders to Anti-TNF Treatment in Rheumatoid Arthritis
Cristina Sobrino¹, Borja Hernández-Breijo², Israel Gañán-Nieto¹, Carlota García-Hoz¹, Victoria Navarro-Compán², Ana Martínez², Javier Bachiller¹, María Gema Bonilla Hernán², Dora Pascual-Salcedo², Garbiñe Roy¹, Mónica Vázquez¹, Alejandro Balsa², Luisa María Villar¹, Chamaida Plasencia² and Eulalia Rodríguez-Martín¹, ¹Immuno-Rheumatology research group, IRYCIS. Ramón y Cajal University Hospital, Madrid, Spain, ²Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain
Background/Purpose: TNF inhibitors (TNFi) are the most common biologicalagents used as disease-modifying treatment in rheumatoid arthritis (RA). Although these drugs have contributed to change the…
Abstract Number: 2823 • 2018 ACR/ARHP Annual Meeting
Comparative Long-Term Effectiveness of Switching to Another Tumour Necrosis Factor Antagonists, Tocilizumab or Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to a First-Line TNF Inhibitor
Daniela Santos Faria¹, Mónica Eusébio², Joana Leite Silva³, Joana Ramos Rodrigues¹, Joana Sousa Neves¹, Ana Catarina Duarte⁴, Carina Lopes⁵, Ana Valido⁶, Joana Dinis⁶, João Freitas⁷, Mariana Santiago⁷, Raquel Ferreira⁸, Sara Ganhão⁹, Luís Cunha Miranda¹⁰, Daniela Peixoto¹, Filipa Teixeira¹, Sérgio Alcino¹, Carmo Afonso¹, José Tavares Costa³ and Maria José Santos¹¹, ¹Rheumatology, ULSAM, Ponte de Lima, Portugal, ²Sociedade Portuguesa de Reumatologia, Lisboa, Portugal, LIsboa, Portugal, ³Rheumatology, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, ⁴Rheumatology, Hospital Garcia de Orta, Almada, Portugal, ⁵Rheumatology, Hospital de Egas Moniz - Centro Hospitalar Lisboa Ocidental, EPE, Lisbon, Portugal, ⁶Rheumatology, Centro Hospitalar Lisboa Norte, Lisbon, Portugal, ⁷Rheumatology, Centro Hospitalar e Universitário de Coimbra, CHUC-EPE, Coimbra, Portugal, ⁸Rheumatology, Centro Hospitalar de São João, Oporto, Portugal, ⁹Rheumatology, Centro Hospitalar de São João, Porto, Portugal, ¹⁰Instituto Português de Reumatologia, Lisbon, Portugal, ¹¹Reuma.pt, Almada, Portugal, Almada, Portugal
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) are highly effective treatments for active Rheumatoid Arthritis (RA). However, up to 40% of patients either fail to respond…
Abstract Number: 639 • 2018 ACR/ARHP Annual Meeting
Is a Primary Good Response to Nsaids Predictive of the Subsequent Response to the First TNF Inhibitor in Patients with Early Axial Spondyloarthritis ?
Loukianos Couvaras¹, Daniel Wendling², Vanessa Pauly³, Vincent Pradel⁴, Anna Molto⁵, Pierre Lafforgue¹ and Thao Pham⁶, ¹Rheumatology, Aix-Marseille University, APHM, Marseille, France, ²service de rhumatologie, CHU J Minjoz, Besancon, France, ³Public Health, Aix-Marseille university, AP-HM, Marseille, France, ⁴Public Health, APHM, Marseille, France, ⁵Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, ⁶Rheumatology Department, Aix-Marseille University, APHM, Marseille, France
Background/Purpose: Good response to NSAIDs is a SpA feature included in classification criteria for axial spondyloarthritis (axSpA). Among patients eligible for a TNF inhibitor (TNFi),…
Abstract Number: 2829 • 2018 ACR/ARHP Annual Meeting
The Response to TNF-Blockers Treatment of Spa Patients Is Influenced By the Interplay between HLA-B27 and Gut Microbiota Composition at Baseline
Marie Vallier¹, Maxime Dougados², Stephanie Ferreira³, Silvia Menegatti⁴, Elisabetta Bianchi⁵, Lars Rogge⁵, Mathias Chamaillard¹ and Corinne Miceli-Richard², ¹CIIL - U1019 - NLRII, Institut Pasteur, Lille, France, ²Rheumatology Department, Paris Descartes University, Paris, France, ³Genoscreen, Lille, France, ⁴Immunology, Immunoregulation Unit, Institut Pasteur, Paris, France, ⁵Immunology, Institut Pasteur, Paris, France
Background/Purpose: The response to TNF-blockers in axial spondyloarthritis (AxSpA) is at least partially influenced by HLA-B27 through a still poorly understood mechanism. Given that HLA-B27…
Abstract Number: 921 • 2018 ACR/ARHP Annual Meeting
Multi-Omics Analysis Identifies a Gene Signature Associated with the Clinical Response to Anti-TNF Therapy in Rheumatoid Arthritis
Adrià Aterido¹, Jesús Tornero², Francisco J Blanco³, Benjamin Fernandez Gutierrez⁴, Antonio Gonzalez⁵, Juan D. Cañete⁶, Joan Maymó⁷, Mercedes Alperi-López⁸, Alejandro Olivé-Marqués⁹, Hector Corominas¹⁰, Víctor Martínez-Taboada¹¹, Isidoro Gonzalez-Alvaro¹², Antonio Fernandez-Nebro¹³, Alba Erra¹⁴, Simón Sánchez-Fernández¹⁵, María López-Lasanta¹, Mireia López-Corbeto¹, Raül Tortosa¹, Laia Codó¹⁶, Sara Marsal¹ and Antonio Julià¹, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, ³Rheumatology Department, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ⁴Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain, ⁵Laboratorio Investigación 10 and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁶Rheumatology Service, Hospital Clínic of Barcelona, Barcelona, Spain, ⁷Rheumatology Department, Hospital del Mar, Barcelona, Spain, ⁸Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, ⁹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁰Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ¹¹Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹²Rheumatology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ¹³UGC de Reumatología, Instituto de Investigación Biomédica de Málaga (IBIMA) Hospital Regional Universitario de Málaga Departamento de Medicina y Dermatología, Universidad de Málaga, MÁLAGA, Spain, ¹⁴Rheumatology Service, Hospital San Rafael, Barcelona, Spain, ¹⁵Rheumatology Department, Hospital General La Mancha Centro, Ciudad Real, Spain, ¹⁶Life Sciences Department, Barcelona Supercomputing Centre, Barcelona, Spain
Background/Purpose: Rheumatoid arthritis (RA) is the most common inflammatory arthritis affecting up to 1% of the population. Tumor Necrosis Factor (TNF) inhibitors have significantly improved…
Abstract Number: 2831 • 2018 ACR/ARHP Annual Meeting
High Need for Anti-TNF Therapy after Withdrawal Strategy in Early Peripheral Spondyloarthritis
Philippe Carron¹, Gaëlle Varkas², Thomas Renson³, Roos Colman⁴, Dirk Elewaut⁵ and Filip van Den Bosch⁶, ¹Department of Rheumatology, Ghent University Hospital and VIB Ghent University, Ghent, Belgium, ²Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, Ghent University Hospital and VIB Ghent University, Ghent, Belgium, ³Department of Rheumatology, Ghent University Hospital, Ghent, 9000, Belgium, ⁴Department of Public Health, Ghent University, Ghent, Belgium, Biostatistics Unit,Ghent University, Ghent, Belgium, Ghent, Belgium, ⁵Ghent University Hospital and VIB Ghent University, Ghent, Belgium, ⁶Rheumatology, Ghent University Hospital and VIB Ghent University, Gent, Belgium
Background/Purpose: Treatment with TNFi in early stages of peripheral Spondyloarthritis (pSpA) results in higher rates of clinical remission, compared to treatment in more longstanding disease.…

« Previous Page
1
…
3
4
5
6
7
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].